NovaBridge Biosciences appointed Martin Dewhurst as an independent director effective September 8, 2026, also adding him to its Audit and Compensation committees. The appointment gives investors a new board member with healthcare strategy, governance and advisory experience, while the company said his independent perspective will support board oversight and long-term value creation.
Key Highlights
- Martin Dewhurst spent his career at McKinsey & Company from 1992 to April 2023.
- Martin Dewhurst was appointed as an independent director effective September 8, 2026.
- Dewhurst joined NovaBridge’s Audit Committee and Compensation Committee.
NovaBridge Biosciences (NASDAQ: NBP) appointed Martin Dewhurst as an independent director effective September 8, 2026. He also joined the Board’s Audit Committee and Compensation Committee.
Dewhurst Adds Healthcare Governance Experience
Dewhurst worked at McKinsey & Company from 1992 to April 2023. His earlier roles included engagement manager at Arthur Andersen & Co. and Marketing manager at BP Solar. He serves on Cytovation’s Remuneration Committee and chairs Distalmotion’s Audit Committee.
Board Oversight And Independent Perspective
The appointment followed the departure of independent director Liu Xin. NovaBridge thanked Liu for her service and contributions to the company. Chairman Fu Wei said Dewhurst’s healthcare, strategy and governance experience would add value as NovaBridge grows and evolves.
FAQs
Q: Who is Martin Dewhurst at NovaBridge Biosciences?
A: Martin Dewhurst is an independent director of NovaBridge Biosciences and serves on its Audit and Compensation committees. He joined the Board effective September 8, 2026.
Q: What committees did Martin Dewhurst join?
A: Dewhurst joined NovaBridge Biosciences’ Audit Committee and Compensation Committee as an independent director, effective September 8, 2026. The filing states that his appointment followed independent director Liu Xin’s departure.
Q: What was Martin Dewhurst’s previous experience?
A: Dewhurst worked at McKinsey & Company from 1992 to April 2023, including leadership roles in its Health Institute and Global Life Sciences Practice. He also serves on several healthcare boards.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.